PL BioScience appoints Oliver Dick as chief technology officer

Ella Day | June 12, 2025 | Appointment | Clinical trials supplies & documentation logistics, Manufacturing and Production, Research and Development Corporate, Devices, Human Platelet Lysate, PL Bioscience, animal-free cell culture, life sciences 

PL BioScience, a German life sciences company specialising in the production and development of human platelet lysate (HPL) for cell expansion, has announced the strengthening of its management team with the appointment of Oliver Dick as chief technology officer. This intends to support HPL upscaling in alignment with growing global demand for its animal-free cell culture solutions.

Dick is an experienced operations executive with over 30 years of experience in project and line management, specialising in process optimisation, cost reduction and digital transformation. Prior to joining PL BioScience, he was an operations consultant at ODICON and chief operating officer at both Resolve BioSciences and Miltenyi Biotec. Additionally, he held a number of senior leadership roles at QIAGEN and Pharmaplan.

“Oliver has an extensive track record in operational excellence and brings a strategic vision as well as hands-on leadership to our team,” said Hatim Hemeda, CEO of PL BioScience. “We are delighted to have him as we enter into this exciting phase.”

Advertisement

HPL is a human-derived cell culture supplement used to support the growth and expansion of cells in clinical research, especially in cell therapy, stem cell and regenerative medicine applications.

“The company is in an excellent position to shape the market globally. I look forward to working with the team,” commented Dick.

Ella Day

12/6/25

Related Content

Lilly opens fourth US Gateway Labs site

Eli Lilly has opened its newest Lilly Gateway Labs (LGL) site in San Diego, California, …

drug-trials

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence

LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …

Lilly secures conditional MHRA approval for new blood cancer treatment

Crown Bioscience opens new US model development centre

Crown Bioscience, a US global contract research organisation (CRO) that is part of JSR Life …

The Gateway to Local Adoption Series

Latest content